Abstract An array of studies implicate different classes of protease and their endogenous inhibitors in multiple sclerosis (MS) pathogenesis based on expression patterns in MS lesions, sera, and/or cerebrospinal fluid (CSF). Growing evidence exists regarding their mechanistic roles in inflammatory and neurodegenerative aspects of this disease. Proteolytic events participate in demyelination, axon injury, apoptosis, and development of the inflammatory response including immune cell activation and extravasation, cytokine and chemokine activation/inactivation, complement activation, and epitope spreading. The potential significance of proteolytic activity to MS therefore relates not only to their potential use as important biomarkers of disease activity, but additionally as prospective therapeutic targets. Experimental data indicate that understanding the net physiological consequence of altered protease levels in MS development and progression necessitates understanding protease activity in the context of substrates, endogenous inhibitors, and proteolytic cascade interactions, which together make up the MS degradome. This review will focus on evidence regarding the potential physiologic role of those protease families already identified as markers of disease activity in MS; that is, the metallo-, serine, and cysteine proteases.
Introduction
Multiple Sclerosis (MS) is considered a complex and heterogeneous multifocal demyelinating disease of the central nervous system (CNS) which is of undetermined origin. Several theories regarding the initiating event have emerged, and these include a viral, or autoimmune cause [61] , or metabolically dependent neurodegenerative changes that promote inflammation, all on a background of genetic susceptibility [13, 28] . While the initiating event in MS is not known and likely a combination of factors participate, the prevailing view of pathogenesis is that it involves a pro-inflammatory assault on CNS white matter driven by autoreactive T cells and activated macrophages, among other immune cells, which results in myelin destruction, axon and neuron degeneration, and irreversible neurological deficits [24, 266] . Regardless of whether the triggering event is viral, autoimmune, and/or metabolic, the effector processes promoting demyelination and axon injury are multifactorial and include cytokines, chemokines, and the focus of this review, proteases. The range of potential involvement of proteolytic activity in MS pathogenesis extends from parenchymal degenerative events, including myelin destruction and axon injury, to release of antigenic self epitopes, immune cell activation, and permeabilization of the blood-brain barrier (BBB).
Since the overall function of proteases involves hydrolytic breakdown of proteins and polypeptides, they have found functional roles in an array of physiologic activities including digestion, fertilization, cellular proliferation and differentiation, cell signaling and migration, wound healing, apoptosis, angiogenesis, and inflammatory responses. While proteases were once viewed as nonspecific degradative enzymes associated with protein catabolism, it is now clear that many proteases hydrolyze highly specific peptide bonds, resulting in limited substrate modification. Limited proteolysis is dictated by protease specificity and activation, accessibility of substrate peptide bonds, and availability of protease inhibitors, or a combination of these, and represents an essential mechanism mediating precise control of cellular processes. By processing bioactive molecules, proteases regulate the availability and function of a wide range of proteins responsible for initiation, modulation, and termination of important cellular activities. Physiologic roles in maintaining a healthy state and in driving inflammatory, respiratory, cardiovascular, neurodegenerative, and immunological diseases, as well as certain types of cancer and viral infections, have been described. Widespread involvement in health and disease makes proteases very attractive targets for development of new drugs for treatment of a variety of conditions including MS.
